Joshua Brumm
2021 - Dyne Therapeutics
In 2021, Joshua Brumm earned a total compensation of $4.1M as President and Chief Executive Officer at Dyne Therapeutics, a 66% decrease compared to previous year.
Compensation breakdown
Non-Equity Incentive Plan | $451,830 |
---|---|
Option Awards | $1,509,121 |
Salary | $562,000 |
Stock Awards | $1,550,653 |
Other | $13,007 |
Total | $4,086,611 |
Brumm received $1.6M in stock awards, accounting for 38% of the total pay in 2021.
Brumm also received $451.8K in non-equity incentive plan, $1.5M in option awards, $562K in salary and $13K in other compensation.
Rankings
In 2021, Joshua Brumm's compensation ranked 3,276th out of 12,415 executives tracked by ExecPay. In other words, Brumm earned more than 73.6% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 3,276 | 74th |
Manufacturing | 1,329 | 76th |
Chemicals And Allied Products | 540 | 77th |
Drugs | 480 | 77th |
Pharmaceutical Preparations | 333 | 79th |
Brumm's colleagues
We found two more compensation records of executives who worked with Joshua Brumm at Dyne Therapeutics in 2021.
News
Dyne Therapeutics CEO Joshua Brumm's 2022 pay rises 6% to $4.3M
April 7, 2023
Dyne Therapeutics CEO Joshua Brumm's 2021 pay falls 66% to $4.1M
April 22, 2022
Dyne Therapeutics CEO Joshua Brumm's 2020 pay jumps 981% to $12M
April 14, 2021
Kaleido Biosciences CEO Alison Lawton's 2019 pay falls 57% to $2.9M
May 8, 2020